spacer
home > ict > winter 2009 > china: delivering clinical excellence
PUBLICATIONS
International Clinical Trials

China: Delivering Clinical Excellence

OVERVIEW OF THE DRUG MARKET

2008 was one of the busiest years for China with regards to the establishment and revision of drug and medical policies. The pharmaceutical industries again began to thrive after a depression lasting several years. The aggregate amount spent by hospitals on purchasing drugs grew by 32.76 per cent year-on-year in the first half of 2008, four per cent higher than in 2007. The accumulated purchasing amount of medical products over seven classifications amounted to US$28.8 billion during the period of January to July all over the country, which is a yearly growth of 13.15 per cent.

The top 10 drugs used throughout hospitals indicate that anti-tumour drugs, cardiovascular drugs and digestive system drugs have been gaining more and more attention in clinical use.

OVERVIEW OF DRUG APPLICATION SYSTEM OF CHINA

The China State Food and Drug Administration (SFDA) divides chemical drugs into six categories according to world pharmaceutical development status. Those drugs not yet launched onto the market of any country are classified as category 1 or 2, and are regarded as new drugs. Clinical trials from Phase I to Phase III are needed before drugs can be launched, followed by a large sample Phase IV trial conducted soon after they are released onto the market according to regulations. Category 3 to Category 5 are those drugs which are launched in markets other than China, although they are also administrated as new drugs with simplified clinical trial procedures compared to those in Category 1 or 2. Generic drugs are considered to be Category 6. Although products of this category are not new, a Bio-equivalence (BE) study is required before they can be launched onto the market.

Drug development in China runs along the same lines as in other countries, consisting of several steps, including compound screening, preclinical research, clinical trial application, clinical trial, registration application, launch and marketing, and so on. The steps with considerable differences to developed nations are ‘approval system for clinical trial’ and ‘certification system for clinical trial institution’.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Xunting Zeng has decades of experience in the field of clinical trials. Dr Zeng received his PhD at Kansai Medical University, Osaka, Japan, before going on to work as a Special Investigator at the International Medical Center of Japan. Several years later he joined the InCROM Group, a Japanese-based international contract research organisation. Dr Zeng is currently General Manager of InCROM China.

spacer
Dr Xunting Zeng
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AstroNova introduces its range of grass paper labels derived from grass for high quality organic products

Dietzenbach, 29 April 2019, AstroNova GmbH, European headquarters of AstroNova Inc. (RI, USA), responsible for Sales and Customer Service in Europe, the Middle East and Africa (EMEA), is extending its Product Identification range with new approved labelling for direct foodstuff contact.
More info >>

White Papers

Managing GxP Environmental Systems to Ensure Data Integrity

Vaisala Ltd


More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement